Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"High Remnant Cholesterol is Associated with the Development of Diabetic Kidney Disease in Patients with Type 2 Diabetes.","authors":"Zhuo Chen, Yan Shen, Xiangjun Chen, Jinbo Hu, Lina Mao, Rui Lan, Xue Li, Hanwen Ye, Wenjin Luo, Yao Qin, Shumin Yang, Qifu Li, Zhihong Wang","doi":"10.2147/DMSO.S542648","DOIUrl":"10.2147/DMSO.S542648","url":null,"abstract":"<p><strong>Aim: </strong>The study aimed to explore the associations of the remnant cholesterol (RC) levels with the risk of diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>The study collected data from 23324 patients with T2DM from the UK Biobank (UKB) cohort and 3059 patients with T2DM from the Chongqing Diabetes Registry (CDR) cohort. UKB and CDR cohort were followed for incident DKD until October 2020 and March 2023, respectively. Cox proportional hazards regression was performed to explore the relationship between RC levels and incident DKD.</p><p><strong>Results: </strong>Participants from the UKB and CDR were followed for a mean period of 13.72 years and 1.92 years, respectively. The incidences of DKD are 12.9% and 24.5%. Participants were divided into 4 groups: 0.41 mmol/L or less, 0.41 to 0.56 mmol/L, 0.56 to 0.73 mmol/L, and greater than 0.73 mmol/L according to RC levels. Lower RC levels (≤0.41 mmol/L) were used as a reference, multi-adjusted model showing that patients with higher RC levels (>0.73 mmol/L) in the UKB were associated with increased risk of incident DKD [hazard ratio [HR], 1.27; 95% CI, 1.10-1.46; P = 0.001]. These results were consistent in the CDR [HR (95% CI): 1.39 (1.03, 1.89); P = 0.034]. In the stratified analyses, we observed an increase in the risk of incident DKD with RC in the elderly patients, while not in the middle-aged patients in both UKB cohort [HR (95% CI): 1.33 (1.13, 1.57) vs 1.16 (0.89, 1.50), P for interaction = 0.043] and CDR cohort [HR (95% CI): 1.53 (1.02, 2.30) vs 1.23 (0.76, 2.00), P for interaction = 0.009].</p><p><strong>Conclusion: </strong>High RC might be an independent risk factor for new-onset DKD in T2DM population after adjusting for traditional risk factors, especially in elderly T2DM patients.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3563-3573"},"PeriodicalIF":3.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145136922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide-2 as a Potential Biomarker for Nonalcoholic Fatty Liver Disease in Children with Obesity: Preliminary Assessment of Metabolic Associations and Underlying Mechanisms.","authors":"Shu-Juan Zhang, Ke Xu, Feng Zhu, Yi-Qun Teng, Yan-Fei Tang, Hong-Wei Xu","doi":"10.2147/DMSO.S528780","DOIUrl":"10.2147/DMSO.S528780","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the effects of glucagon-like peptide-2 (GLP-2) on insulin resistance and lipid metabolism, as well as potential mechanisms contributing to the development of non-alcoholic fatty liver disease (NAFLD) in children with obesity.</p><p><strong>Methods: </strong>A cross-sectional study was conducted involving 107 children with obesity, aged between 5 and 15 years, including 55 with NAFLD and 52 without NAFLD. Anthropometric assessments and fasting blood samples were collected to evaluate GLP-2, plasma glucose, insulin (INS), lipids, leptin (LEP), and adiponectin (ADPN). Correlation and logistic regression analyses were performed to evaluate associations between GLP-2 and metabolic parameters.</p><p><strong>Results: </strong>Children with NAFLD exhibited significantly higher levels of GLP-2, LEP, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose (FPG), INS, and the homeostasis model assessment of insulin resistance index (HOMA-IR) (all <i>p</i><0.05), along with significantly lower levels of ADPN and high-density lipoprotein cholesterol (HDL-C) compared with those without NAFLD (<i>p</i><0.05). GLP-2 concentrations correlated positively with TC (<i>r</i>=0.42), TG (<i>r</i>=0.51), LDL-C (<i>r</i>=0.38), FPG (<i>r</i>=0.61), INS (<i>r</i>=0.58), HOMA-IR (<i>r</i>=0.61), and LEP (<i>r</i>=0.42), and negatively with ADPN (<i>r</i>=-0.53; all <i>p</i><0.01). In univariate analysis, GLP-2 was identified as a risk factor for NAFLD (odds ratio [OR]=1.225, 95% confidence interval [CI]: 1.001-1.499, <i>p</i><0.05); however, the association was attenuated after adjustment for body mass index (OR=1.112, <i>p</i>=0.102). ADPN retained a protective association (OR=0.771, <i>p</i><0.05).</p><p><strong>Conclusion: </strong>GLP-2 may contribute to the pathophysiology of insulin resistance and dyslipidemia in pediatric NAFLD, potentially via modulation of adipokine activity. These findings suggest GLP-2 as a candidate biomarker and possible therapeutic target in this population.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3515-3525"},"PeriodicalIF":3.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoas Muscle Index, Systemic Inflammation, and Liver Fibrosis in MAFLD: A Case-Control Study.","authors":"Lijuan Yu, Nan Jiang, Huichun Wu, Jie Li, Shenjie Xu","doi":"10.2147/DMSO.S521829","DOIUrl":"10.2147/DMSO.S521829","url":null,"abstract":"<p><strong>Objective: </strong>Investigating psoas muscle index (PMI) as a potential biomarker for metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatic fibrosis through a case-control study.</p><p><strong>Methods: </strong>This case-control study enrolled 80 MAFLD patients and 80 healthy controls from our hospital (2023-2024). Abdominal CT-derived PMI, inflammatory markers, and FIB-4 scores were assessed. ROC and logistic regression analyses evaluated PMI's diagnostic potential for MAFLD and associated fibrosis.</p><p><strong>Results: </strong>A total of 160 patients met the inclusion criteria. Compared with the non-MAFLD group, the PMI and systemic inflammatory indicators in the MAFLD group were higher. In MAFLD patients, PMI was significantly correlated with systemic inflammation indicators, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) (P<0.001, P=0.038, and P<0.001, respectively). ROC curve analysis showed that the areas under the ROC curve (AUC) of PMI and other systemic inflammatory indicators (PLR, NLR, LMR, SII) for diagnosing MAFLD were 0.615, 0.526, 0.956, 0.803, and 0.674, respectively. The AUC of PMI combined with LMR, NLR, and LMR plus NLR for diagnosing MAFLD were 0.547, 0.585, and 0.572, respectively. FIB-4 was linearly correlated with PMI and systemic inflammatory indicators (PLR, NLR, SII) (r=-0.208, P=0.008; r=-0.211, P=0.007; r=0.327, P<0.001; r=0.164, P=0.039). The combination of PMI and systemic inflammatory indicators (PLR, NLR, SII) demonstrated a good diagnostic ability for liver fibrosis in MAFLD (AUC=0.602, P=0.003).</p><p><strong>Conclusion: </strong>PMI significantly correlates with systemic inflammation and hepatic fibrosis in MAFLD patients, serving as a diagnostic biomarker. Combined with inflammatory markers, it improves non-invasive screening efficacy for MAFLD/fibrosis. This study pioneers incorporating muscle metabolism into MAFLD diagnosis, with potential for primary care translation. Dynamic PMI monitoring may assess \"muscle-liver axis\" targeted therapies.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3527-3538"},"PeriodicalIF":3.0,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12452978/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145130331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"METTL3-Mediated m⁶A Regulation of GDF11 Promotes Socket Healing in Diabetic Rats.","authors":"Ding Guo, Bin Zhang","doi":"10.2147/DMSO.S536806","DOIUrl":"10.2147/DMSO.S536806","url":null,"abstract":"<p><strong>Purpose: </strong>Tooth extraction socket healing is impaired in diabetes. We investigated whether the RNA-methyltransferase METTL3 could rescue this defect in an experimental animal study.</p><p><strong>Methods: </strong>Twelve-week-old male GK and Wistar rats received lentiviral overexpression or knockdown of METTL3 in the extraction socket. Socket healing was evaluated by micro-CT, histology and Quantitative real-time PCR (RT-qPCR). RNA immunoprecipitation (RIP) and dual-luciferase reporter assays were performed to study the interaction between METTL3 and GDF11.</p><p><strong>Results: </strong>GK rats exhibited significantly lower body weight and METTL3 expression compared to Wistar rats (p<0.001). Micro-CT showed a 50% decrease in BV/TV versus diabetic controls (P < 0.001), accompanied by lower Tb.N and higher Tb.Sp (<i>p</i> < 0.001). Overexpression of METTL3 enhanced tooth extraction socket healing in GK rats, as evidenced by improved bone trabeculae formation and soft tissue healing (<i>p</i><0.001). METTL3 increased GDF11 expression and stability through m⁶A modification at a specific site (<i>p</i><0.001). Knockdown of GDF11 partially reversed the tooth extraction socket healing effects of METTL3 overexpression (<i>p</i><0.01).</p><p><strong>Conclusion: </strong>METTL3-mediated m⁶A methylation of GDF11 enhances socket healing in diabetic rats, identifying METTL3 as a potential therapeutic target for oral wound repair in diabetes.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3505-3514"},"PeriodicalIF":3.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145112143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α-ALA Attenuates Cardiac Injury in Diabetic Heart Disease Mice by Modulating Inflammation and AMPKα1.","authors":"Xuan Liu, Landi Wang, Weiwei Dong, Yuchao Wang, Dayong Li","doi":"10.2147/DMSO.S537517","DOIUrl":"10.2147/DMSO.S537517","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic heart disease (DHD) is systolic and/or diastolic dysfunction of the heart muscle that occurs in patients with the presence of Type 2 diabetes mellitus. AMPKα1, a key regulator of glucose metabolism, has been shown to promote glucose uptake and catabolism. Alpha-linolenic acid (α-ALA) is an essential fatty acid that helps to prevent cardiovascular disease and is very important for human health. However, its role as a medical agent in preventing DHD by modulating AMPKα1is unknown.</p><p><strong>Methods: </strong>An experimental type 2 diabetic mouse model was established by treating animals with a high-fat diet (HFD) for four weeks and intraperitoneal injection of streptozotocin (STZ) (50 mg/kg body weight). After induction of type 2 diabetes, the animals were treated orally with α-ALA (2 or 4 g/kg) for twelve weeks.</p><p><strong>Results: </strong>The type 2 diabetic mice showed an increase in blood glucose levels, a decrease in body weight and cardiac dysfunction. Diabetic mice treated with α-ALA attenuated hyperglycaemia, dyslipidaemia, and cardiac dysfunction. In addition, α-ALA improved histological changes and fibrosis in HFD/STZ-induced mice. Type 2 diabetes in mice exacerbated the inflammatory status. α-ALA treatment significantly attenuated inflammation in diabetic hearts. The underlying mechanisms for this attenuation involved modulation of AMPKα1.</p><p><strong>Conclusion: </strong>The results of this study provide evidence that α-ALA protects against HFD/STZ (T2DM)-induced cardiac injury by alleviating inflammation and upregulating AMPKα1.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3491-3503"},"PeriodicalIF":3.0,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Astragaloside IV Improves Cognitive Impairment by Reducing β-Amyloid and Tau Protein Deposition in Hippocampal Tissue of db/db Mice: A PET/CT Imaging-Based Study.","authors":"Lei Jiang, Yanchao Lu, Pei Yin, Dan Liu, Chengshuo Duan, Yong Wang","doi":"10.2147/DMSO.S526076","DOIUrl":"10.2147/DMSO.S526076","url":null,"abstract":"<p><strong>Purpose: </strong>Diabetic Cognitive Impairment is a frequent diabetes complication with few treatments. Astragaloside IV (AS-IV), a lanosterol-derived saponin, shows significant neuroprotection. This study used PET/CT to assess the effects of AS-IV on β-amyloid (Aβ) and tau protein buildup in the hippocampus of db/db mice and to investigate the underlying mechanisms involved.</p><p><strong>Methods: </strong>Eighteen diabetic db/db mice were divided into three groups: a model group, and two treatment groups receiving AS-IV at 20 mg/kg and 40 mg/kg (n=6 each). A control group of db/m mice (n=6) was also included. Treated mice were administered AS-IV daily, while the model and control groups were administered saline for eight weeks. Biweekly, mice were assessed for body weight and fasting blood glucose. Insulin sensitivity was tested using the OGTT, and cognitive function was evaluated with the MWM. Aβ deposition was observed with ¹⁸F-AV45 PET and Congo red staining, tau protein deposition with ¹⁸F-MK6240 PET, and neurofibrillary tangles with silver staining. TNF-α levels and proteins related to the EGFR/NF-κB pathway were analyzed in blood and hippocampal tissue.</p><p><strong>Results: </strong>The study found that AS-IV reduced weight gain (<i>P</i> < 0.05), lowered fasting glucose (<i>P</i> < 0.01-0.001), and improved glucose tolerance (<i>P</i> < 0.05-0.001) in db/db mice. Behavioral tests showed that AS-IV treatment decreased escape latency (<i>P</i> < 0.05-0.01), increased time in the target quadrant (<i>P</i> < 0.05-0.001), and raised the number of platform crossings (<i>P</i> < 0.05-0.001). ¹⁸F-AV45 PET, ¹⁸F-MK6240 PET, Congo red staining and silver staining revealed reduced Aβ (<i>P</i> < 0.05-0.001) and tau protein (<i>P</i> < 0.01) deposits in the hippocampus. ELISA and immunofluorescence assays indicated a significant decrease in TNF-α expression in serum (<i>P</i> < 0.05-0.001) and hippocampus (<i>P</i> < 0.01-0.001), while Western blot analyses showed inhibition of the EGFR/NF-κB signaling pathway.</p><p><strong>Conclusion: </strong>This study found that AS-IV improved cognitive function in diabetic db/db mice by reducing the buildup of Aβ and tau proteins in the hippocampus via the TNF-α-activated EGFR/NF-κB pathway.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3477-3490"},"PeriodicalIF":3.0,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12442921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity and Its Comorbidities: Current Treatment Options, Emerging Biological Mechanisms, Future Perspectives and Challenges.","authors":"Lihua Wang, Qian Wang, Yumo Xiong, Wei Shi, Xiao Qi","doi":"10.2147/DMSO.S540103","DOIUrl":"10.2147/DMSO.S540103","url":null,"abstract":"<p><p>Obesity is a chronic, multifactorial disease and a major global public health challenge. Defined by excessive fat accumulation, obesity significantly increases the risk of numerous diseases, including type 2 diabetes mellitus (T2DM), cardiovascular disease, heart failure, and metabolic dysfunction-associated steatotic liver disease, contributing to rising morbidity and mortality rates worldwide. Although several pharmacological treatments have demonstrated notable efficacy in weight management, concerns regarding drug safety remain a significant challenge. Metabolic bariatric surgery (MBS) has emerged as the most effective intervention for achieving long-term and sustained weight loss; however, it is typically reserved for advanced stages of the disease. Moreover, the role of MBS in managing obesity-related comorbidities remains a topic of ongoing debate. In this review, we provide a comprehensive analysis of the epidemiology of obesity and its associated comorbidities, along with the latest insights into the mechanisms underlying obesity-induced chronic complications. Growing evidence highlights the crucial role of imbalances between white and brown adipose tissues, alterations in gut microbiota, genetic and epigenetic modifications, and immune system dysregulation in driving obesity and its related conditions. These emerging insights have unveiled numerous potential therapeutic targets with promising weight-reducing effects. Furthermore, advancements in our understanding of signal transduction pathways may pave the way for future multimodal therapeutic strategies in obesity management, ushering in a new era of precision medicine.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3427-3445"},"PeriodicalIF":3.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inverse Association Between the Dawn Phenomenon and Thyroid Feedback Quantile-Based Index in Type 2 Diabetes Using Continuous Glucose Monitoring: A Cross-Sectional Study.","authors":"Yan Xia, Hong-Jing Chen, Reng-Na Yan, Xiao-Wei Zhu, Han Zhao, Bo Ding, Yun Hu","doi":"10.2147/DMSO.S543452","DOIUrl":"10.2147/DMSO.S543452","url":null,"abstract":"<p><strong>Purpose: </strong>The mechanism of the dawn phenomenon remains poorly understood, and no targeted therapies are currently available. Emerging evidence suggests thyroid dysfunction may contribute to dawn phenomenon by modulating hepatic glucose output, insulin sensitivity, and β-cell function. This study utilized continuous glucose monitoring (CGM) to identify patients with type 2 diabetes exhibiting dawn phenomenon and to investigate its association with thyroid feedback efficiency.</p><p><strong>Patients and methods: </strong>This study included patients with type 2 diabetes. All patients underwent CGM before any adjustments to their glucose-lowering therapy. The dawn phenomenon was determined if the elevation of blood glucose from 3 AM to 7 AM was more than 1.11 mmol/L. Clinical data, including medications, diabetic complications and comorbidities, biochemical markers, hemoglobin A1c (HbA1c), beta-cell function, and thyroid function, were recorded.</p><p><strong>Results: </strong>A total of 524 patients were included, of whom 265 (50.6%) exhibited the dawn phenomenon. A control group of 216 patients was matched based on HbA1c levels from those without dawn phenomenon using propensity score matching. The standard deviation of blood glucose (SDBG) (2.26 vs 1.78, P=0.001) and coefficient of variation (CV) (22.86 vs 16.97, P<0.001) were significantly higher in the dawn phenomenon group compared to the non-dawn phenomenon group. Thyroid feedback quantile-based index (TFQI) of free thyroxine (FT4) was negatively correlated with the elevation of blood glucose from 3 AM to 7 AM (BG 3-7) (r=-0.211, P=0.002). Low-density lipoprotein (LDL) showed a positive correlation with fasting blood glucose (r=0.242, P=0.001) and BG 3-7 (r=0.123, P=0.083). Regression analysis indicated that TFQI of free triiodothyronine (FT3) (β=-2.399, P<0.001) and LDL (β=0.550, P=0.004) were independent predictors of BG 3-7.</p><p><strong>Conclusion: </strong>The dawn phenomenon significantly correlates with glycemic fluctuation severity and TFQI. These findings indicate the relationship between thyroid hormones and glucose regulation, providing new insights into the mechanism of the dawn phenomenon.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3465-3475"},"PeriodicalIF":3.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145079928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Prediction Model for Osteoporotic Fracture in Type 2 Diabetes Patients: A Nomogram Approach Based on a Single-Center Retrospective Study.","authors":"Peng Fei Liu, Yan Xin Ren, Peng Wang, Xiu Mei Ma, Kang Geng","doi":"10.2147/DMSO.S475409","DOIUrl":"10.2147/DMSO.S475409","url":null,"abstract":"<p><strong>Background: </strong>To address the high disability and mortality rates of osteoporotic fracture (OPF), a common complication of type 2 diabetes mellitus (T2DM), this study seeks to create an early OPF risk prediction model for T2DM patients.</p><p><strong>Methods: </strong>A single-center retrospective study was conducted on 868 T2DM patients using Multi-dimensional data. The dataset was split into training and validation sets at an 8:2 ratio. Through logistic regression analyses, key predictive factors were pinpointed and incorporated into a Nomogram prediction model. The model's reliability, validity, and generalizability were assessed using various statistical methods, including the Hosmer-Lemeshow test, Receiver Operator Characteristic (ROC) curve analysis, and decision curve analysis. The validation set was used to test the model.</p><p><strong>Results: </strong>Female gender (OR 2.681, 95% CI 1.046-6.803, P=0.04), age (OR 1.068, 95% CI 1.023-1.115, P=0.003), body mass index (BMI) (OR 0.912, 95% CI 0.851-0.979, P=0.010), blood lactic acid level (OR 0.747, 95% CI 0.597-0.935, P=0.011), lumbar T-score (OR 0.644, 95% CI 0.499-0.833, P=0.001), and femoral neck T-score (OR 0.412, 95% CI 0.292-0.602, P<0.001) were identified as independent factors predicting OPF in T2DM patients. Based on these factors, a Nomogram model was constructed. The model showed a high degree of agreement with actual data (Hosmer-Lemeshow test, P=0.406), with an Area Under the Curve (AUC) value of 0.831. It demonstrated good clinical benefits across different thresholds and excellent generalization ability on the validation set.</p><p><strong>Conclusion: </strong>This study integrated key factors such as gender, age, BMI, lactic acid, lumbar spine, and femoral neck T-values to construct a Nomogram for predicting the risk of OPF in T2DM patients. This model can assist doctors in accurately assessing the risk of OPF in T2DM patients, facilitating early detection and timely treatment. It has significant clinical practical value.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3447-3464"},"PeriodicalIF":3.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12435361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Assessment of Diabetes-Dependent Quality of Life in Polish Patients.","authors":"Ewelina Bąk, Grzegorz Zawiła, Robert Skalik, Sylwia Krzemińska, Bogusława Kupczak-Wiśniowska, Lukas Kober, Elena Gurková","doi":"10.2147/DMSO.S527529","DOIUrl":"10.2147/DMSO.S527529","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the impact of type 2 diabetes mellitus (T2DM) on quality of life (QoL) among Polish patients, comparing those with diabetic foot syndrome (DFS) to those without, using the Audit of Diabetes-Dependent QoL (ADDQoL) questionnaire.</p><p><strong>Patients and methods: </strong>The study was conducted among 50 patients with DFS and 50 without DFS. In relation to the first group, two scales (PEDIS and the Wagner scale) were used to assess the severity of wounds. The tool used for studying QoL was the Polish language version of ADDQoL, comprising two questions related to general QoL and 19 domains related to some aspects of life. Each domain included 2 components. The value of the average weighted impact (AWI) score is derived by dividing the sum of the weighted ratings by the number of applicable domains. Demographic and clinical parameters were also applied.</p><p><strong>Results: </strong>Patients with T2DM demonstrated a negative influence of the disease in all domains of ADDQoL. Values of AWI of ADDQoL showed significant associations with patients. Patients with DFS experienced a negative impact on their QoL, especially regarding physical health, feelings about their future, and working life. Patients without DFS were particularly affected in terms of freedom to eat and drink, and feelings about their future. These findings underscore the need for targeted interventions to improve QoL among DFS patients, particularly addressing physical health and future outlook.</p><p><strong>Conclusion: </strong>The study concludes that DFS significantly worsens QoL across multiple domains. Gender, treatment methods, and self-care practices positively influence QoL, while complications such as amputation and wound severity negatively impact it. Tailored strategies are needed to address these factors.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"3387-3401"},"PeriodicalIF":3.0,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433654/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}